Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Target Lowered at Royal Bank Of Canada

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective decreased by analysts at Royal Bank Of Canada from $345.00 to $280.00 in a report released on Friday, Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada‘s target price would indicate a potential upside of 65.78% from the stock’s current price.

Other equities research analysts also recently issued reports about the stock. Jefferies Financial Group raised their target price on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a “hold” rating in a research note on Tuesday, September 8th. Morgan Stanley decreased their target price on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a research note on Friday, July 31st. Raymond James Financial downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and decreased their price objective for the company from $420.00 to $315.00 in a report on Friday. UBS Group began coverage on shares of Alnylam Pharmaceuticals in a report on Thursday, October 15th. They set a “buy” rating and a $354.00 target price for the company. Finally, Needham & Company LLC dropped their price objective on shares of Alnylam Pharmaceuticals from $357.00 to $243.00 and set a “buy” rating for the company in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $331.38.

Alnylam Pharmaceuticals Trading Down 2.9%

ALNY traded down $5.10 on Friday, hitting $168.90. The company had a trading volume of 1,544,875 shares, compared to its average volume of 1,492,568. The company has a market cap of $22.60 billion, a PE ratio of 31.13 and a beta of 0.28. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The business’s fifty day simple moving average is $237.78 and its 200 day simple moving average is $287.22. Alnylam Pharmaceuticals has a 12-month low of $168.80 and a 12-month high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the previous year, the business posted $2.90 earnings per share. The business’s revenue was up 16.7% compared to the same quarter last year. Equities research analysts expect that Alnylam Pharmaceuticals will post 6.43 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares in the company, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Toth Financial Advisory Corp acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $25,000. Keating Financial Advisory Services Inc. acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth approximately $42,000. Burkett Financial Services LLC acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at $37,000. CoreCap Advisors LLC increased its position in Alnylam Pharmaceuticals by 744.4% during the third quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 134 shares during the last quarter. Finally, Ascentis Independent Advisors purchased a new stake in Alnylam Pharmaceuticals during the first quarter worth approximately $64,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 16.7% year over year to $1.46 billion, exceeding the $1.43 billion consensus estimate. Reported EPS of $16.26 also surpassed expectations, although the result was significantly boosted by a roughly $1.9 billion tax benefit. Alnylam Q3 earnings and revenue results
• Positive Sentiment: Management reaffirmed its fiscal 2026 outlook and anticipates $4.2 billion to $4.5 billion in TTR product sales, supporting the company’s near-term revenue base. Alnylam TTR sales outlook and TRITON-CM expansion
• Positive Sentiment: Needham maintained a “buy” rating, with a reduced $243 price target that still implies substantial upside, while Alnylam highlighted continued progress across its RNAi pipeline. Needham analyst rating
• Neutral Sentiment: Alnylam expanded the Phase 3 TRITON-CM study of nucresiran to approximately 2,250 patients while retaining an expected launch timeline around 2030. The larger trial may improve the evidence base but also raises development costs and reinforces the long wait for a potential revenue contribution. Alnylam pipeline and nucresiran update
• Negative Sentiment: Investors reacted negatively to indications that U.S. Amvuttra and Onpattro sales growth is slowing, reducing the impact of the earnings beat and raising concerns about the pace of future growth. Alnylam sales growth analysis
• Negative Sentiment: Stifel downgraded ALNY from “buy” to “hold” with a $225 target, followed by Bernstein’s downgrade from “outperform” to “market perform” with a $199 target. Although both targets remain above the recent trading level, the rating changes signal reduced conviction and added selling pressure. Stifel downgrade

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.